Related Experiment Videos
Thrombophlebitis in cancer patients
Annals of the New York Academy of Sciences
|January 1, 1981
Summary
Heparin therapy is superior to oral anticoagulants for managing migratory thrombophlebitis in advanced cancer patients. However, reduced antithrombin-III levels can impact heparin efficacy, necessitating careful monitoring.
Area of Science:
- Oncology
- Hematology
- Vascular Medicine
Background:
- Advanced cancer patients with multiple metastases often experience thrombotic complications.
- Migratory thrombophlebitis, a serious condition, can significantly impact patient mobility and quality of life.
Observation:
- Five non-ambulatory cancer patients (lung, breast, head and neck) presented with migratory thrombophlebitis.
- Laboratory findings revealed a hypercoagulable state with decreased antithrombin-III (AT-III) levels, despite normal fibrinogen and slightly elevated Fibrinogen Degradation Products (FDP).
- Initial heparin therapy, while prolonging Partial Thromboplastin Time (PTT), showed delayed resolution of thrombophlebitis symptoms.
Findings:
- Heparin therapy, at high doses (30,000-36,000 units/day), was less effective than anticipated in resolving thrombophlebitis, suggesting impaired antithrombotic action potentially due to low AT-III.
- Recurrence of thrombophlebitis was observed even with Coumadin therapy, indicating challenges in anticoagulation management in this patient cohort.
- Heparin's efficacy is dependent on adequate AT-III levels, and its long-term use feasibility requires further investigation regarding optimal discontinuation timing.
Implications:
- Heparin demonstrates superior efficacy over oral anticoagulants for controlling thrombophlebitis in advanced cancer.
- The study highlights the critical role of antithrombin-III levels in the effectiveness of heparin therapy for cancer-associated thrombosis.
- Further research is needed to establish optimal anticoagulation strategies and duration for patients with advanced malignancy and thrombotic events.